Form 4: Adaptive Biotechnologies Officer Sells Shares for Tax Cover

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, sold 63,103 shares of common stock at $13.17 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Sharon Benzeno, Chief Commercial Officer of Immuno-Medicine at Adaptive Biotechnologies Corp (ADPT), reported a transaction involving company common stock.
• On March 11, 2026, Benzeno disposed of 63,103 shares of common stock.
• The shares were sold at a price of $13.17 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The transaction does not represent a discretionary trade by the reporting person.
• Following this transaction, Benzeno beneficially owns 272,751 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was non-discretionary and solely for tax purposes related to RSU vesting, which is a standard practice for executive compensation and does not reflect a change in management's confidence.

Positives

• The sale was non-discretionary, solely to cover tax withholding obligations in connection with the vesting of RSUs, indicating it was not a voluntary decision to reduce exposure to the company's stock.

Negatives

• A significant number of shares (63,103) were disposed of by a key executive, reducing their direct beneficial ownership.

Future Outlook

NA

Management Comments

• "This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person."

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine practice for executives receiving equity compensation, such as Restricted Stock Units (RSUs). These sales are typically pre-arranged and non-discretionary, designed solely to meet tax obligations upon vesting, and are generally not indicative of a change in management's sentiment or outlook on the company's future performance, unlike discretionary insider sales.

Stakeholder Impact

• Shareholders: The sale results in a minor reduction in insider ownership, but its non-discretionary nature mitigates concerns about executive confidence in the company's future.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting. It is explicitly stated as non-discretionary and therefore does not reflect a change in the executive's confidence or outlook on the company. As such, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Sharon Benzeno, Beneficial Ownership